Clinical data | |
---|---|
Trade names | Capastat |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682860 |
Pregnancy category |
|
Routes of administration | intramuscular |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C25H44N14O8 |
Molar mass | 668.717 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Capreomycin is an antibiotic which is given in combination with other antibiotics for the treatment of tuberculosis.[1] Specifically it is a second line treatment used for active drug resistant tuberculosis.[1] It is given by injection into a vein or muscle.[1]
Common side effects include kidney problems, hearing problems, poor balance, and pain at the site of injection.[1] Other side effects include paralysis resulting in the inability to breathe.[1] It is not recommended with streptomycin or other medications that may damage the auditory vestibular nerve.[1] It is not recommended during pregnancy as it may cause kidney or hearing problems in the baby.[1] Capreomycin is commonly grouped with the aminoglycoside family of medications.[2] How it works is unclear.[1]
Capreomycin was discovered from Streptomyces capreolus in 1960.[3] It was removed from the World Health Organization's List of Essential Medicines in 2019.[4]